GLP1R and type 2 diabetes mellitus: A preliminary trial for the efficacy of TZT in the management of T2DM showed that this drug was less effective compared to semaglutide (an analogue of GLP-1) in the reduction of insulin resistance (IR) and glycated hemoglobin (HbA1c) (Frías et al. 2021).